Sponsored Links
MedicalResources
| Merck Reports Results Of Phase III Study Of Investigational Oral Allergy Immunotherapy Tablet (AIT) In Patients Ages 5-17 With Grass Pollen Allergy |
 |
 |
 |
| Medical News - Allergy | |||
|
In new data from a Phase III study in 345 children and adolescents (ages 5-17 years), patients with grass pollen allergic rhinoconjunctivitis treated with Merck's investigational sublingual grass (Phleum Pratense) allergy immunotherapy tablet (AIT) showed a 26 percent greater improvement in the total combined score (daily symptom score and daily medication score), compared to p... Read more: Allergy News From Medical News Today
|